| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
6-Geranylnaringenin (0-80 µM; 12, 24 hours) induces a dose- and time-inhibitory substantial increase in cell proliferation in cancer cell lines [2]. (0-60 µM; 24 hours) A549 cells need to be satisfied for caspases to be triggered. The accumulation of G1/M-phase and G2/G1-phase cells in A549 cells is enhanced by 6-geranylnaringenin. 6-Geranylnaringenin 60 µM; 24 hours) causes self-inflicted The autophagic process is harmed[2].
|
|---|---|
| ln Vivo |
6-Geranylnaringenin (25 mg/kg; gavage; administered 48 and 24 hours prior to DSS, then every 24 days thereafter; continued for 5) alleviates humiditis symptoms and postpones its consequences [3].
|
| Cell Assay |
Cell Proliferation Assay [2]
Cell Types: Human Lung Cancer A549, Breast Cancer MCF-7, Colon Cancer HCT116, and Osteosarcoma U2OS Cell Tested Concentrations: 20, µM; 24 hrs (hours)) Significant Reduce the levels of p53 and phosphorylated mTOR [2]. 40, 60, 80 µM Incubation Duration: 12, 24 hrs (hours) Experimental Results: Significant inhibition of cell proliferation in these cancer cell lines in a dose- and time-dependent manner. Apoptosis analysis[2] Cell Types: A549 Cell Tested Concentrations: 0-60 µM Incubation Duration: 24 hrs (hours) Experimental Results: Annexin V/PI positive cells increased Dramatically in a dose- and time-dependent manner. Induces apoptosis through caspase-3 activation and PARP cleavage. Cell cycle analysis[2] Cell Types: A549 Cell Tested Concentrations: 0-60 µM Incubation Duration: 24 hrs (hours) Experimental Results: Accumulation of apoptotic sub-G1 cells increased in a dose-dependent manner. The number of G2/M phase cells also increased in a dose-dependent manner. Autophagy assay [2] Cell Types: A549 Cell Tested Concentrations: 60 µM Incubation Duration: 24 h Experimental Results: A |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats (180-220 g) [3]
Doses: 25 mg/kg Route of Administration: gavage; 48 hrs (hrs (hours)) and 24 hrs (hrs (hours)) before DSS (10% (w/v)) and every 24 hrs (hrs (hours)) thereafter ; Results for 5 days: Improved colitis symptoms and delayed its onset. DAI was lower on the last day of the experiment. |
| References |
|
| Additional Infomation |
Bonannione A has been reported to have been found in hops, alder sesame, and other organisms with available data.
|
| Molecular Formula |
C25H28O5
|
|---|---|
| Molecular Weight |
408.49
|
| Exact Mass |
408.193
|
| CAS # |
97126-57-3
|
| PubChem CID |
5716903
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.219±0.06 g/cm3
|
| Boiling Point |
647.8±55.0 °C at 760 mmHg
|
| Melting Point |
116-118 °C
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
642
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2C([H])=C(C(C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])=C(C=2C(C([H])([H])[C@@]1([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)O[H])O[H]
|
| InChi Key |
XYIQIBWIEGCVQY-RWHUQTJRSA-N
|
| InChi Code |
InChI=1S/C25H28O5/c1-15(2)5-4-6-16(3)7-12-19-20(27)13-23-24(25(19)29)21(28)14-22(30-23)17-8-10-18(26)11-9-17/h5,7-11,13,22,26-27,29H,4,6,12,14H2,1-3H3/b16-7+/t22-/m0/s1
|
| Chemical Name |
(2S)-6-[(2E)-3,7-dimethylocta-2,6-dienyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
|
| Synonyms |
Mimulone 6 Geranylnaringenin 6Geranylnaringenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4480 mL | 12.2402 mL | 24.4804 mL | |
| 5 mM | 0.4896 mL | 2.4480 mL | 4.8961 mL | |
| 10 mM | 0.2448 mL | 1.2240 mL | 2.4480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
